 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| 12345678910111213...507508» |
- | doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: Possible pathogenic mechanisms for doxorubicin-induced splenic atrophy in a human breast cancer xenograft mouse model. (Pubmed Central) - Jun 29, 2024
Further analysis revealed that the loss of regulators and effectors of the oxidative defense system, including sirtuin (Sirt)3, Sirt5, superoxide dismutase (SOD)1, and SOD2, was implicated in the upstream regulation of caspase-dependent cellular apoptosis. These findings provide insights on the pathogenic mechanisms underlying doxorubicin-induced splenic atrophy and suggest that further investigation may be warranted to explore strategies for managing potential side effects in breast cancer patients treated with doxorubicin.
- | acetylcysteine solution / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: Ultrasonographic and histopathological investigation of the effect of N-acetylcysteine on doxorubicin-induced ovarian and uterine toxicity in rats. (Pubmed Central) - Jun 29, 2024
These findings provide insights on the pathogenic mechanisms underlying doxorubicin-induced splenic atrophy and suggest that further investigation may be warranted to explore strategies for managing potential side effects in breast cancer patients treated with doxorubicin. NAC, an antioxidant, attenuated DOX-induced gonadotoxicity in rats.
- | doxorubicin hydrochloride / Generic mfg.
Journal: An alternative approach of TUNEL assay to specifically characterize DNA fragmentation in cell model systems. (Pubmed Central) - Jun 28, 2024
Cells were exposed to resveratrol (RSV) and doxorubicin (Doxo), in single and combined treatments...Instead, MDA-MB-231 cells showed few or no fragmented metaphase, suggesting a probable activation of DNA repair mechanisms. By applying this alternative approach of TUNEL test, we obtained data that can more specifically characterize DNA fragmentation for a suitable application in various fields.
- | doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: The cytokine response of human coronary artery endothelial cells treated with doxorubicin: results of an in vitro experiment. (Pubmed Central) - Jun 28, 2024
Under these conditions the following genes were downregulated: IL10, IL1R2, TNF. Cultivation of cells in the presence of doxorubicin (2 ?g/ml and 6 ?g/ml) for 24 h also increased the secretion of IL-6.
- | Preclinical, Journal: Relationships Among Serological Indicators and In Vitro High-Throughput Drug Sensitivity Screening Results in Patients with Hepatocellular Carcinoma. (Pubmed Central) - Jun 27, 2024
NLR, SII, and SIRI were correlated with FOLFOX4, and the higher the values of NLR, SII, and SIRI, the higher the in vitro inhibition of FOLFOX. Also, NLR was correlated with XP, and the higher the value of NLR, the higher the in vitro inhibition of XP.
- | doxorubicin hydrochloride / Generic mfg.
Journal: PICALM Regulating the Generation of Amyloid ?-Peptide to Promote Anthracycline-Induced Cardiotoxicity. (Pubmed Central) - Jun 27, 2024
This alleviates the doxorubicin-induced cardiotoxicity in vitro and in vivo. In human heart tissue samples of patients with chemotherapy-induced cardiotoxicity, PICALM, and amyloid ?-peptide are elevated as well.
- | Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku, Rituxan (rituximab) / Roche
Journal, Head-to-Head: Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study. (Pubmed Central) - Jun 27, 2024
We demonstrated that rituximab-abbs was noninferior to rituximab in both effectiveness and safety among patients receiving R-CHOP for DLBCL in this study. Long-term follow-up would be needed to confirm these results.
- | doxorubicin hydrochloride / Generic mfg.
Journal: A case report of primary pericardial sarcoma. (Pubmed Central) - Jun 27, 2024
Transthoracic echocardiogram and computed tomography are often the initial tests of choice for pericardial effusions with pericardiocentesis recommended for effusions with tamponade physiology, for moderate-to-large effusions, or if there is concern for infection/neoplasm. Due to improved tissue characterization and spatial resolution, CMR and positron emission tomography should also be considered for atypical or recurrent pericardial effusions to assess for less common aetiologies such as malignancy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Acid-Responsive Decomposable Nanomedicine Based on Zeolitic Imidazolate Frameworks for Near-Infrared Fluorescence Imaging/Chemotherapy Combined Tumor Theranostics. (Pubmed Central) - Jun 27, 2024
Here, we present a one-pot method for the synthesis of uniform Cy5.5&DOX@ZIF-8 nanoparticles in mixed solvents, efficiently achieving simultaneous encapsulation of hydrophilic doxorubicin (DOX) and hydrophobic Cyanine-5.5 (Cy5.5)...Enhanced therapeutic efficiency was observed in composite NPs compared to free DOX, validating tumor-targeted capability. These findings suggest ZIF-8-based nanomedicines as promising platforms for multifunctional tumor theranostics.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Cytotoxic Effects of Doxorubicin on Cancer Cells and Macrophages Depend Differently on the Microcarrier Structure. (Pubmed Central) - Jun 27, 2024
The DOX-containing calcium carbonate microparticles with a protective polyelectrolyte shell were more toxic to the cancer cells than DOX-containing polyelectrolyte microcapsules, whereas, for the macrophages, the microcapsules were most toxic. It is concluded that DOX-containing core/shell microparticles with an eight-layer polyelectrolyte shell are optimal drug microcarriers due to their low toxicity to immune cells, even upon prolonged incubation, and strong delayed cytotoxicity against tumor cells.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Hybrid Nanosystem Formed by DOX-Loaded Liposomes and Extracellular Vesicles from MDA-MB-231 Is Effective against Breast Cancer Cells with Different Molecular Profiles. (Pubmed Central) - Jun 27, 2024
The hybrid nanosystem was produced by film hydration, and doxorubicin (DOX) was encapsulated in this system using the ammonium sulfate gradient method...Preliminary acute toxicity assessments using Balb/C female mice indicated a median lethal dose of 15-17.5 mg/kg, with no evidence of splenic, liver, heart, bone marrow, and renal damage at a dose of 15 mg/kg. These findings suggest the hybrid formulation as a versatile nanocarrier for the treatment of various breast cancer subtypes.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Novel Ultrasound-Responsive Amyloid Formulation. (Pubmed Central) - Jun 27, 2024
The potential of the aggregates as a drug depot was assessed in lung cancer cells, using Doxorubicin (Dox) as a model drug...Moreover, the RIP3/F127/Dox amyloid formulations that were subjected to ultrasound treatment exhibited greater toxicity to lung cancer cells compared to that of Dox alone at equal concentrations. Overall, the results from this proof-of-concept study show that amyloidogenic peptide aggregates with stimuli-responsive properties can be utilized as efficient drug delivery depots.
- | pentoxifylline / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal, IO biomarker: Activation of AMPK/mTOR-Driven Autophagy and Suppression of the HMGB1/TLR4 Pathway with Pentoxifylline Attenuates Doxorubicin-Induced Hepatic Injury in Rats. (Pubmed Central) - Jun 27, 2024
Together, for the first time, our findings demonstrate the ameliorative effect of PTX against DOX-evoked hepatotoxicity by dampening the hepatic HMGB1/TLR4/NF-?B pro-inflammatory axis and augmenting hepatic AMPK/mTOR-driven autophagy. Thus, PTX could be utilized as an adjunct agent with DOX regimens to mitigate DOX-induced hepatic injury.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Chemical Composition, Antioxidant, and Cytotoxic Activity of Essential Oils in the Above-Ground Parts of Sonchus oleraceus L. (Pubmed Central) - Jun 27, 2024
Thus, PTX could be utilized as an adjunct agent with DOX regimens to mitigate DOX-induced hepatic injury. Using doxorubicin as a reference therapy, the MTT assay findings revealed that this oil had remarkable inhibitory effects on the proliferation of HepG2 cancer cell lines, with an IC50 of 136.02
- | doxorubicin hydrochloride / Generic mfg.
Journal: Anticancer Therapies Based on Oxidative Damage: Lycium barbarum Inhibits the Proliferation of MCF-7 Cells by Activating Pyroptosis through Endoplasmic Reticulum Stress. (Pubmed Central) - Jun 27, 2024
In addition, LBE did not display cytotoxicity toward healthy human cells but demonstrated antioxidant properties by neutralizing ROS generated by doxorubicin. These findings underscore the potential of LBE as a highly promising natural extract in cancer therapy.
- | seliciclib (CYC202) - Cyclacel, Cedars / Sinai
Journal: Cytoprotective Role of Autophagy in CDIP1 Expression-Induced Apoptosis in MCF-7 Breast Cancer Cells. (Pubmed Central) - Jun 27, 2024
We also demonstrated that treatment with the cyclin-dependent kinase 5 (CDK5) inhibitor roscovitine led to an increase in the electrophoretic mobility of CDIP1...Treatment of cells expressing CDIP1 with SAR405, an inhibitor of the class III phosphatidylinositol 3-kinase VPS34, caused a reduction in autophagy and promoted apoptosis. Therefore, autophagy is thought to be a defense mechanism against CDIP1 expression-induced apoptosis.
- | doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: Naphthoquinone-Quinolone Hybrids with Antitumor Effects on Breast Cancer Cell Lines-From the Synthesis to 3D-Cell Culture Effects. (Pubmed Central) - Jun 27, 2024
The synthesized compounds demonstrated selective cytotoxicity against Luminal and triple-negative breast cancer (TNBC) cells, which represent the two main molecular types of breast cancer that depend most on cytotoxic chemotherapy, with potency comparable to doxorubicin, a standard chemotherapeutic widely used in breast cancer treatment...The pharmacokinetics of the synthesized compounds were predicted using the SwissADME webserver, indicating that these compounds exhibit favorable drug-likeness properties and potential as antitumor agents. Overall, our findings underscore the promise of these hybrid compounds as potential candidates for breast cancer chemotherapy, emphasizing their selectivity and efficacy.
- || Clinical, Journal: Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries. (Pubmed Central) - Jun 27, 2024
Based on the lack of differences in progression-free and overall survival after a median follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part; n = 395) randomizing VAD induction (vincristin/adriamycin/dexamthasone)/tandem-transplantation/thalidomide-maintenance vs. PAD induction (bortezomib/adriamycin/dexamethasone)/tandem transplantation/bortezomib maintenance, we discern how chromosomal aberrations determine long-term prognosis by different patterns of association with proliferation and treatment-dependent response, whether responses achieved by different regimens are equal regarding prognosis, and whether subpopulations of patients could be defined as treatable without upfront "novel agents" in cases of limited resources, e.g., in low- or middle-income countries...Significantly fewer patients reach a near-complete response or better with "conventional" (VAD) vs. bortezomib-based treatment after induction or high-dose melphalan...Associations with faster and deeper responses can be deceptive in the case of prognostically adverse aberrations 1q21+ and t(4;14). Far from advocating a return to "outdated" treatments, if resources do not permit state-of-the-art-treatment, normal renal function and/or molecular profiling identifies patient subpopulations doing well without upfront "novel agents".
- | doxorubicin hydrochloride / Generic mfg.
Journal: Analysis of mutation-originated gain-of-glycosylation using mass spectrometry-based N-glycoproteomics. (Pubmed Central) - Jun 26, 2024
The integration of site- and structure-specific N-glycoproteomics approach, conjugating with GoG characterization, provides a universal workflow for revealing comprehensive N-glycosite and N-glycan structure information of GoG. The analysis of mutation-originated GoG can be extended to GoG characterization of other N-glycoproteome systems including complex clinical tissues and body fluids.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Preparation and characterization of chitosan-coated noisomal doxorubicin for enhanced its medical application. (Pubmed Central) - Jun 26, 2024
The findings from this study will contribute to the knowledge of the physical and chemical properties of the synthesized formulation, which is crucial for ensuring its stability, drug release kinetics, and biological activity. The enhanced chitosan-coated noisomal doxorubicin has the potential to improve the effectiveness and safety of doxorubicin in cancer treatment, offering a promising strategy for enhanced medical applications.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Targeted chemo-phototherapy in red light with novel doxorubicin and iron(III) complex-functionalized gold nanoconjugate (Dox-Fe@FA-AuNPs). (Pubmed Central) - Jun 26, 2024
Additionally, under red light irradiation, the nanoconjugate generated ROS, inducing caspase-3/7-dependent apoptosis with a photo-index (PI) >50, and inhibited cancer cell migration. Our findings underscore the potential of Dox-Fe@FA-AuNPs as a highly effective and sustainable platform for targeted chemo-phototherapy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Programmable Tetrahedral DNA-RNA Nanocages Woven with Stimuli-Responsive siRNA for Enhancing Therapeutic Efficacy of Multidrug-Resistant Tumors. (Pubmed Central) - Jun 26, 2024
Herein, stimuli-responsive programmable tetrahedral DNA-RNA nanocages (TDRN) have been rationally designed and developed for dynamic co-delivery of the chemotherapeutic drug doxorubicin and P-glycoprotein (P-gp) siRNA...These biocompatible and multifunctional TDRN nanocarriers with gold nanocluster-assisted delivery (TDRN@Dox@AuNCp) are successfully used to achieve synergistic RNAi/Chemo-therapy in vitro and in vivo. This programmable TDRN drug delivery system, which integrates RNAi therapy and chemotherapy, offers a promising approach for treating multidrug-resistant tumors.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Doxorubicin induces deglycosylation of cancer cell-intrinsic PD-1 by NGLY1. (Pubmed Central) - Jun 26, 2024
The maintenance of PD-1 sensitizes tumor cells to Dox-mediated antiproliferative effects. Our study unveils a regulatory mechanism of PD-1 in response to Dox and highlights a potential role of cancer cell-intrinsic PD-1 in Dox-mediated antitumor effects.
- | ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Clinical features and outcomes of young patients with low-grade non-rhabdomyosarcoma soft tissue sarcomas treated with a risk-based strategy: A report from Children's Oncology Group study ARST0332. (Pubmed Central) - Jun 26, 2024
P3
Our study unveils a regulatory mechanism of PD-1 in response to Dox and highlights a potential role of cancer cell-intrinsic PD-1 in Dox-mediated antitumor effects. Most low-risk patients with completely resected POG low-grade NRSTS are successfully treated with surgery alone, and surgical margins greater than 1
- | doxorubicin hydrochloride / Generic mfg.
Journal: HnRNPA2B1 ISGylation Regulates m6A-Tagged mRNA Selective Export via ALYREF/NXF1 Complex to Foster Breast Cancer Development. (Pubmed Central) - Jun 26, 2024
HnRNPA2B1 knockdown or mRNA export inhibition can result in the retention of nuclear m6A-tagged mRNA associated with stemness maintenance, which suppresses BCSCs self-renewal and effectively improves the efficacy of doxorubicin therapy. These findings demonstrate the pivotal role of m6A-modified mRNA nuclear export in BC progression, highlighting that the inhibition of m6A-tagged mRNA and its nuclear export is a potential therapeutic strategy for the amelioration of cancer chemotherapy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: A Triple-Responsive Polymeric Prodrug Nanoplatform with Extracellular Ros Consumption and Intracellular H2 O2 Self-generation for Imaging-Guided Tumor Chemo-Ferroptosis-Immunotherapy. (Pubmed Central) - Jun 26, 2024
In vivo results indicate that the nanoplatform strengthens tumor ICD, induces cytotoxic T lymphocytes proliferation, inhibits 4T1 tumor regression and metastasis, and prolongs survival median. In all, we propose a new strategy in strengthening ICD and T cells activity cascade with ferroptosis as well as immune checkpoint blockade for effective tumor immunotherapy.
- | doxorubicin hydrochloride / Generic mfg.
Journal, Immunogenic cell death: An Ultrasound-Triggered STING Pathway Nanoagonist for Enhanced Chemotherapy-Induced Immunogenic Cell Death. (Pubmed Central) - Jun 26, 2024
In all, we propose a new strategy in strengthening ICD and T cells activity cascade with ferroptosis as well as immune checkpoint blockade for effective tumor immunotherapy. Herein, a controllable ultrasound (US)-triggered chemo-immunotherapy nanoagonist is successfully synthesized by utilizing the pH and reactive oxygen species (ROS) dual-responsive PEG-polyphenol to assemble sonosensitizer zinc oxide (ZnO) and doxorubicin (DOX)...Subsequently, both the dsDNA and zinc ions bind with cyclic GMP-AMP synthase and activate the stimulator of interferon genes (STING)
- | doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal, IO biomarker: Fucoidan from Lessonia trabeculata Induces Apoptosis through Caspase Dependent and Caspase-Independent Activation in 4T1 Breast Adenocarcinoma In Vitro. (Pubmed Central) - Jun 26, 2024
After 72 h of culture, the IC50 for FLt was 561 ?g/mL, while doxorubicin (Dox) had an IC50 of 0.04 ?g/mL...These findings suggest that FLt may have potential applications in breast cancer treatment. Further research will provide more information to elucidate the mechanism of action of FLt.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Multimodal Mass Spectrometry Imaging of an Osteosarcoma Multicellular Tumour Spheroid Model to Investigate Drug-Induced Response. (Pubmed Central) - Jun 26, 2024
Previously unknown doxorubicin-induced metabolite upregulation was revealed by DESI-MSI of MCTSs, which may be used to inform mechanisms of chemotherapeutic resistance. The demonstration of specific tumour survival mechanisms that are characteristic of those reported for in vivo tumours has underscored the increasing value of this approach as a tool to investigate drug resistance.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Composite Hydrogel with Oleic Acid-Grafted Mesoporous Silica Nanoparticles for Enhanced Topical Delivery of Doxorubicin. (Pubmed Central) - Jun 26, 2024
In vitro cell studies showed that loading in OA-modified nanoparticles significantly improved doxorubicin's cytotoxic effects toward epidermoid carcinoma cells (A431). All of the results suggest that the prepared composite hydrogel has potential for dermal delivery of doxorubicin in the treatment of skin cancer.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Lipid-Based Nanocarrier by Targeting with LHRH Peptide: A Promising Approach for Prostate Cancer Radio-Imaging and Therapy. (Pubmed Central) - Jun 26, 2024
D-P-HLH-coated and anticancer drug doxorubicin (DX)-loaded solid lipid nanoparticles (F-DX-SLN) were formulated by the cold homogenization technique and characterized by Fourier transform infrared spectroscopy, X-ray diffraction, X-ray photoelectron spectroscopy, differential scanning calorimetry, dynamic light scattering, electron microscopy, entrapment efficiency, and drug-release profile studies...Results clearly indicate that F-DX-SLN exhibits sustained and superior targeted administration of anticancer drugs, thus opening up the possibility of a drug delivery system with precise control and targeting effects. F-DX-SLN could also provide a nanotheranostic approach with improved efficacy for prostate cancer therapy.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, HEOR: Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study. (Pubmed Central) - Jun 24, 2024
P3
F-DX-SLN could also provide a nanotheranostic approach with improved efficacy for prostate cancer therapy. No substantial differences in PRO assessments were observed between neoadjuvant pembrolizumab+chemotherapy followed by adjuvant pembrolizumab vs neoadjuvant placebo+chemotherapy in early-stage TNBC.
- | Journal: Characterizing Chemotherapy/Radiotherapy-Induced Genome Chaos in Hodgkin's Lymphoma Patients Using M-FISH. (Pubmed Central) - Jun 24, 2024
This chromosomal instability may play a role in the occurrence of second primary cancers that are observed in 10% of HL survivors. This chapter will describe a protocol for utilizing M-FISH to study treatment-induced genome chaos in Hodgkin's lymphoma (HL) patients, following a brief discussion.
- | Preclinical, Journal, Tumor microenvironment: Immunoregulatory cyclophilin a improves low-dose chemotherapy with a modulation of the immune tumor microenvironment in experimental models of melanoma B16 and lymphoma EL4 in vivo. (Pubmed Central) - Jun 24, 2024
This chapter will describe a protocol for utilizing M-FISH to study treatment-induced genome chaos in Hodgkin's lymphoma (HL) patients, following a brief discussion. RhCypA could be potentially proposed as a perspective component of the combined cancer chemoimmunotherapy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Characterization of C-phycocyanin antioxidant, anti-inflammatory, anti-tumour, and anti-HCoV-229E activities and encapsulation for implementation in an innovative functional yogurt. (Pubmed Central) - Jun 24, 2024
Anti-human liver and colon carcinomas that exceeded Doxorubicin with very low cytotoxicity against normal cell lines were detected...The results prove that C-PC from spirulina algae is a renewable source of dyes. The encapsulation process using phytosomes gave it high stability against environmental influences, and therefore, it can be applied in the food and pharmaceutical industries in the future.
- | doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: The combination of Curcumin and Doxorubicin on targeting PI3K/AKT/mTOR signaling pathway: an in vitro and molecular docking study for inhibiting the survival of MDA-MB-231. (Pubmed Central) - Jun 24, 2024
These in silico and in vitro findings can be a new horizon for further in vitro and clinical trials of breast cancer treatment. The online version contains supplementary material available at 10.1007/s40203-024-00231-2.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Gypenosides exert cardioprotective effects by promoting mitophagy and activating PI3K/Akt/GSK-3?/Mcl-1 signaling. (Pubmed Central) - Jun 24, 2024
The pharmacological effects of GYPs in cardioprotection, mitochondrial function, mitochondrial quality control, and underlying mechanisms were further investigated in Doxorubicin (Dox)-stimulated H9c2 cardiomyocytes...Mechanistically, the phosphorylation of PI3K, Akt, GSK-3?, and the protein level of Mcl-1 was upregulated by GYP treatment. Our findings reveal that GYPs exert cardioprotective effects by rescuing the defective mitophagy, and PI3K/Akt/GSK-3?/Mcl-1 signaling is potentially involved in this process.
- || Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Review, Journal: A rare case of Richter transformation with breast involvement: A case report and literature review. (Pubmed Central) - Jun 24, 2024
The patient is in the process of receiving follow-up treatment. We also performed a comprehensive literature review on RT, with particular emphasis on its biological paradigm, prognosis implications, existing therapeutic approaches, and emerging directions in treatment modalities.
- || cisplatin / Generic mfg.
Retrospective data, Review, Journal, Metastases: Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen. (Pubmed Central) - Jun 22, 2024
Although rates of pathological complete response were not significantly different, pathological downstaging correlated with OS. ddMVAC should be preferred over gemcitabine/cisplatin for patients with muscle-invasive bladder cancer who can tolerate its greater toxicity.
- | Truqap (capivasertib) / Otsuka, AstraZeneca
Journal, Video: Toto-Cell: A new software to analyze cellular events during video-microscopy. (Pubmed Central) - Jun 21, 2024
In conclusion, our software is an important tool to facilitate the analysis of video-microscopy, in a quantifying and qualifying manner. It enables a higher accuracy when compared to manual calculations.
- | Polivy (polatuzumab vedotin-piiq) / Roche, Brukinsa (zanubrutinib) / BeiGene
New P2 trial: Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL (clinicaltrials.gov) - Jun 21, 2024
P2, N=20, Enrolling by invitation, Sponsor: The First Affiliated Hospital of Soochow University
- ||| Clinical guideline, Review, Journal: Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology. (Pubmed Central) - Jun 21, 2024
This review indicated that G-CSF's efficacy as primary prophylaxis in Ewing sarcoma, except in children, is uncertain despite its common use. This review tentatively endorses intensified chemotherapy with G-CSF primary prophylaxis for Ewing sarcoma.
- | Journal: Subcutaneous Panniculitis-like T Cell Lymphoma Diagnosed with a Slowly Progressive Course: A Case Report. (Pubmed Central) - Jun 21, 2024
After 6 courses of CHOP, CT revealed no disease evidence. He remained in complete remission at 30 months of therapy.
- | AZD7648 / AstraZeneca
Journal: PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT. (Pubmed Central) - Jun 20, 2024
The PRKDC inhibitor AZD7648 and DOX synergized and strongly suppressed the growth of osteosarcoma in mouse xenograft models and human organoids. In conclusion, the PRKDC-GDE2-GNAS-AKT regulatory axis suppresses DOX sensitivity and comprises targetable candidates for improving the efficacy of chemotherapy in osteosarcoma.
- || sorafenib / Generic mfg.
Clinical, Journal: Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial. (Pubmed Central) - Jun 20, 2024
P3
These findings suggest that combined treatment should be used for patients with recurrent intermediate-stage HCC after R0 hepatectomy with positive MVI. ClinicalTrials.gov Identifier: NCT04103398.
- | Rituxan (rituximab) / Roche
Journal, HEOR, Combination therapy: Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP. (Pubmed Central) - Jun 20, 2024
ClinicalTrials.gov Identifier: NCT04103398. The objective of this analysis was to assess the impact of treatment with Sandoz rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on HRQoL in treatment-na
- | ampicillin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Structural investigations and antibacterial, antifungal and anticancer studies on zinc salicylaldimine complexes. (Pubmed Central) - Jun 20, 2024
The objective of this analysis was to assess the impact of treatment with Sandoz rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on HRQoL in treatment-na Among four bacteria, two ligands inhibited Staphylococcus aureus and Escherichia coli (9-10
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas
P2 data, Journal: Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". (Pubmed Central) - Jun 19, 2024
An iAR of at least 70% had a positive predictive value of 0.92 and a negative predictive value of 0.97 in predicting LAR-enriched TNBC according to RNA-based assays. Our data support future trials of AR blockade in early-stage LAR-enriched TNBC.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Outcome of serial cardiac evaluations during doxorubicin-based chemotherapy in small- to medium-sized dogs with multicentric lymphoma. (Pubmed Central) - Jun 19, 2024
The other echocardiographic results were not significantly different between each evaluation. In conclusion, our results showed no significant cardiotoxicity under echocardiogram and electrocardiogram in small- and medium-sized dogs without risk factors for DCM after four doses of doxorubicin in a 30-minute infusion method.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18 F-FDG positron emission tomography. (Pubmed Central) - Jun 19, 2024
Anthracyclines, such as doxorubicin, are important anti-cancer therapies but are associated with arterial injury...In a large animal model, anthracycline exposure was associated with aortic fibrosis. In patients with lymphoma, anthracycline exposure was not associated with aortic inflammation.Further research is required to elucidate the mechanisms of anthracycline-related vascular harm.